SESSIONE POSTER | VENERDÌ 18 NOVEMBRE ORE 11,00

1 Irene Artuso | Milano

2 Nadia Bisso | Genova

3 Giuseppina Camiolo | Catania 4 Elisa Coviello | Genova 5 Elisa Ferretti | Genova 6 Elisa Genuardi | Torino 7 Cesarina Giallongo | Catania 9 Rosa Greco | Cosenza 9 Fabio Guolo | Genova 10 Valeria lachelli | Catania 12 Annamaria Petrungaro | Cosenza 13 Giada Rotunno | Firenze 14 Daniele Tibullo | Catania

15 Stefania Trino | Rionero In Vulture (Pz)

- TMPRSS6 FAVORS HEPCIDIN INHIBITION BY ERYTHROFERRONE IN MICE BY IMPAIRING THE BMP SIGNALING
- EFFICACY AND FEASIBILITY OF FULL PEDIATRIC INDUCTION IN PHILADELPHIA CROMOSOME NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA YOUNGER ADULTS
- HIGH-DENSITY NEUTROPHILS ARE ABERRANTLY ACTIVATED AND IMMUNOSUPPRESSIVE IN MULTIPLE MYELOMA
- EFFICACY AND FEASIBILITY OF R-CODOX-M/IVAC REGIMEN IN AGGRESSIVE DLBCL
- ANTI TUMOR ACTIVITY OF INTERLEUKIN-17RB IN GERMINAL CENTER-DERIVED B CELL LYMPHOMAS
- HASHCLONE: A NEW IGH-NGS APPROACH TO QUANTIFY MINIMAL RESIDUAL DISEASE IN B-CELL LYMPHOMA
- MYELOMA MESENCHYMAL STROMAL CELLS (MSC) CONTRIBUTE TO TUMOR MICROENVIRONMENT TRANSFORMATION
- TREATMENT ACUTE MYELOID LEUKEMIA USING CYTOREDUCTIVE CHEMOTHERAPY CYTARABINE (ARA-C) FOLLOWED AZACITIDINE (AZA) MAINTENANCE: A REAL LIFE SINGLE CENTER EXPERIENCE
- A BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM-LIKE PHENOTYPE IDENTIFIES A SUBGROUP OF NPM1-MUTATED AML PATIENTS WITH WORSE PROGNOSIS
- CHARACTERIZATION OF CD9-CXCL12-CXCR4 EXPRESSION IN BIOLOGICAL SUBTYPES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY FINDINGS AND FUTURE PERSPECTIVES
- 11 Francesco La Rocca | Rionero In Vulture (Pz) MICRORNA-155 IN SERUM EXTRACELLULAR VESICLES IS A POTENTIAL BIOMARKER FOR HEMATOLOGICAL MALIGNANCIES
 - EFFICACY OF ECULIZUMAB IN SEVERE ADAMTS13 DEFICIENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) REFRACTORY TO STANDARD THERAPIES: REPORT OF TWO CASES
 - EPIDEMIOLOGY AND CLINICAL RELEVANCE OF MUTATIONS IN POSTPOLYCYTHEMIA VERA AND POSTESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A STUDY ON 359 PATIENTS OF THE AGIMM GROUP
 - BORTEZOMIB-INDUCED ER STRESS AND AUTOPHAGY ARE MODULATED BY HEME OXYGENASE 1 IN MULTIPLE MYELOMA (MM) CELLS
 - A PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND INHIBITS FYN PHOSPHORYLATION AND INDUCES APOPTOSIS IN NATURAL KILLER CELL LEUKEMIA

FINAL CONTEST | VILLAFRANCA DI VERONA 17-18 NOVEMBRE 2016

GIOVEDÌ 17 NOVEMBRE 2016

VENERDÌ 18 NOVEMBRE 2016

AULE: ROMA | PARIGI | LONDRA

contributi scientifici

8,30 Presentazione e discussione dei

SESSIONI PARALLELE

11.00 SESSIONE POSTER

12.00 SIMPOSIO JANSSEN

12,30 SIMPOSIO NOVARTIS

multiplo

16.00 Chiusura dei lavori

13.30 Lunch

trattamento del mieloma Paola Tacchetti (BO)

Francesco Grimaldi (NA)

13,00 SIMPOSIO Bristol-Myers Squibb

Sara Grammatico (RM)

14.45 Presentazione e premiazione dei vincitori

SESSIONE PLENARIA

AULA ROMA

(Per l'intera giornata non è previsto l'accreditamento ECM)

Moderatori: Mario Boccadoro, Giovanni Pizzolo

Moderatori: Mario Boccadoro, Giorgina Specchia

Aplasia midollare: progressi acquisiti e nuove

Moderatori: Sergio Amadori, Pellegrino Musto

L'immunoterapia in ematologia inizia dal mieloma

frontiere nella terapia non trapiantologica

Gli anticorpi monoclonali: una svolta nel

13,00 Welcome buffet

4.00 Registrazione partecipanti

4,15 Apertura dei lavori

AULA ROMA

SESSIONE PLENARIA SIMPOSIO CELGENE

Luca Franceschini (RM)

Dalla ricerca alla pratica clinica: 10 anni innovazione in ematologia oncologica

Moderatori: Mario Boccadoro, Fabrizio Pane
4,30 Mieloma multiplo: progressi e prospettive future

15,00 Nuovi orizzonti nella terapia delle patologie mieloidi Marta Riva (MI)

SESSIONE EDUCAZIONALE ECM

Moderatori: Mario Boccadoro, Giovanni Pizzolo

Terapie personalizzate nelle mielodisplasie

- Luca Maurillo (RM)
 5,50 Combinazioni terapeutiche con gli anticorpi
- monoclonali nel mieloma multiplo
 Francesca Gay (TO)
- ,10 Tossicità ed impatto del ferro libero su midollo e microambiente midollare Alessandro Isidori (PU)

6.30 Coffee Break

AULE: ROMA | PARIGI | LONDRA SESSIONI PARALLELE

6,45 Presentazione e discussione dei contributi scientifici

,15 Test ECM e chiusura dei lavori del primo giorno

STEERING COMMITTEE:

SERGIO AMADORI, ROMA | MARIO BOCCADORO, TORINO | PAOLO CORRADINI, MILANO | ROBIN FOÀ, ROMA PELLEGRINO MUSTO, RIONERO IN VULTURE (PZ) | FABRIZIO PANE, NAPOLI | GIOVANNI PIZZOLO, VERONA | GIORGINA SPECCHIA. BARI

FACULTY:

EMANUELE ANGELUCCI, CAGLIARI | ALBERTO BOSI, FIRENZE | ROBERTO CAIROLI, MILANO |
CLARA CAMASCHELLA, MILANO | FRANCESCO DI RAIMONDO, CATANIA | BRUNANGELO FALINI, PERUGIA |
RENATO FANIN, UDINE | FELICETTO FERRARA, NAPOLI | GIANLUCA GAIDANO, NOVARA | MARCO GOBBI, GENOVA
FORTUNATO MORABITO, COSENZA | STEFANO A. PILERI, MILANO | PIER LUIGI ZINZANI, BOLOGNA

TALENT SCOUT TEAM:

NICCOLÒ BOLLI, MILANO | PAOLO GALLIPOLI, CAMBRIDGE (UK) | ANTONELLA NAI, MILANO | MARIANGELA PALLADINO, ROMA | CHIARA PALMI, MONZA | DAVIDE ROSSI, BELLINZONA (CH) | MARIA ROSARIA SAPIENZA, BOLOGNA | SARAH TETTAMANTI, MONZA | ENRICO TIACCI, PERUGIA

> PATROCINI: SIE – SOCIETÀ ITALIANA DI EMATOLOGIA SIES – SOCIETÀ ITALIANA DI EMATOLOGIA SPERIMENTALE

> > GOLDEN SPONSOR:







SILVER SPONSOR:



UNDER 40 in HEMATOLOGY

GIOVANI EMATOLOGI A CONFRONTO | 2016



WWW.UNDER40.IT





AULA ROMA GIOVEDÌ 17 NOVEMBRE ORE 16,45		15 Benedetta Accordi Padova	 PHARMACOLOGICAL INHIBITION OF LCK IS ABLE TO REVERT GLUCOCORTICOID RESISTANCE IN PEDIATRIC T-ALL 	AULA PARIGI VENERDÌ 18 NOVEMBRE ORE 8,30		7 Maria Abbattista Milano	THROMBOSIS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AFTER ORTHOTOPIC LIVER TRANSPLANTATION, THE ROLE OF FACTOR V LEIDEN
1 Lucia Brunello Torino2 Giuseppina Uccello Cosenza	 A COMPARATIVE STUDY OF BIOSIMILAR G-CSFS VERSUS ORIGINATOR GCSFS FOR CD34+ CELLS MOBILIZATION AND AUTOGRAFTING IN HEMATOLOGICAL MALIGNANCIES VALIDATION OF THE CLL-IPI AND COMPARISON WITH THE MDACC PROGNOSTIC INDEX: ANALYSIS OF 1364 NEWLY DIAGNOSED PATIENTS 	16 Alessia Pagani Milano17 Fabio Guolo Genova	 BMP6/HEPCIDIN CIRCUIT IN THE LIVER AND ITS RELATIONSHIP WITH ERYTHROPOIESIS MINIMAL RESIDUAL DISEASE DIRECTED THERAPY FOR RELAPSING ACUTE MYELOID LEUKEMIA PATIENTS WITH MUTATED NPM1: 	10 Anna Lucia Fedullo Roma 11 Paola Minetto Genova	 GENOMIC CHARACTERIZATION OF ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL). PROGNOSTIC IMPLICATIONS MINIMAL RESIDUAL DISEASE ASSESSMENT MAY DRIVE CONSOLIDATION THERAPY IN ACUTE MYELOID LEUKEMIA. IT'S TIME FOR MRD-DRIVEN DECISION MAKING 	8 Antonella Teramo Padova9 Alessandra Romano Catania	AND G20210A PROTHROMBIN MUTATION STAT3 MUTATION IMPACTS BIOLOGICAL AND CLINICAL FEATURES OF T-LGL LEUKEMIA THE PROGNOSTIC VALUE OF THE MYELOID-MEDIATED
3 Giada Dal Collo Verona	CRITICAL ROLE OF NOTCH IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FROM CELL LINE TO PATIENTS	18 Elisa Rumi Pavia	 PRELIMINARY RESULTS FROM A PILOT STUDY GENETIC PREDISPOSITION TO FAMILIAL CASES OF MYELOPROLIFERATIVE NEOPLASMS 	12 Federica Lovisa Padova	COMPREHENSIVE CHARACTERIZATION OF PLASMATIC EXOSOMES IN PEDIATRIC ANAPLASTIC LARGE-CELL LYMPHOMA: NEW TOOLS FOR	10 Maria Caterina Rotiroti Monza	IMMUNOSUPPRESSION MARKER ARGINASE-1 IN CLASSIC HODGKIN LYMPHOMA • SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF
4 Bruno Fattizzo Milano	 IMPACT OF BONE MARROW FIBROSIS AND EARLY RESPONSE ON OUTCOME AFTER AZACITIDINE THERAPY IN 94 PATIENTS WITH MYELODISPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA 	19 Alberto Mussetti Milano	 REDUCED-INTENSITY TRANSPLANTATION FOR LYMPHOMAS USING HAPLOIDENTICAL RELATED DONORS VERSUS HLA-MATCHED UNRELATED DONORS 	13 Carlo Zaninetti Pavia	MONITORING CANCER PROGRESSION • PERSONALIZED REFERENCE INTERVALS FOR PLATELET COUNT REDUCE THE PREVALENCE OF UNEXPLAINED THROMBOCYTOPENIA		ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR)
	STUDY OF THE CORRELATIONS OF CLINICAL AND BIOLOGICAL CHARACTERISTICS IN TREATMENT-NAÏVE PATIENTS AFFECTED BY	20 Roberto Mina Torino	 AN INTEGRATED ANALYSIS OF CARDIO-VASCULAR ADVERSE EVENTS OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS ENROLLED IN 3 PHASE I/II TRIALS 	14 Monica Casucci Milano	 LNGFR-SPACED CAR-T CELLS SPECIFIC FOR THE ONCO-ANTIGEN CD44V6 FOR THE IMMUNOTHERAPY OF ACUTE MYELOID LEUKEMIA AND MULTIPLE MYELOMA 	AULA LONDRA VENERDÌ 18 NOVEMBRE ORE 8,30	
	CHRONIC LYMPHOCYTIC LEUKEMIA WITH TRISOMY 12: LDH LEVELS PREDICT PROGRESSION-FREE SURVIVAL			15 Patrizia Sciancalepore Torino	• ATP-BINDING-CASSETTE A1 REGULATES EXTRACELLULAR ISOPENTENYL PYROPHOSPHATE RELEASE AND $V_{\gamma}9V\delta2$ T-CELL ACTIVATION BY	11 Marianna Rossi Rozzano (MI)	 PIATTAFORMA MOLECOLARE "HEME PANEL" PER LO STUDIO DELL'EMOPOIESI CLONALE E SCREENING PRECOCE DELLE SINDROMI MIELODISPLASTICHE
6 Barbara Castella Torino	 IMMUNE CHECKPOINT BLOCKADE COMBINATIONS AS PROMISING STRATEGY FOR CANCER IMMUNOTHERAPY IN MULTIPLE MYELOMA PATIENTS 	ATEGY FOR CANCER IMMUNOTHERAPY IN MULTIPLE MYELOMA AULA PARIGI I GIOVEDÌ 17 NOVEN		16 Manuela Gambella Torino	 DENDRITIC CELLS EVALUATION OF MINIMAL RESIDUAL DISEASE BY ASO-RQ-PCR IN MULTIPLE MYELOMA: RESULTS FROM 2 PHASE III STUDIES IN PATIENTS 	12 Monica Messina Roma	 THE BCR/ABL1-LIKE PREDICTOR: A NEW Q-RT-PCR-BASED TOOL TO IDENTIFY ADULT BCR/ABL1-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA
7 Federica Melazzini Pavia	 CLINICAL AND PATHOGENETIC CHARACTERIZATION OF ETV6-RELATED THROMBOCYTOPENIA, AN INHERITED THROMBOCYTOPENIA PREDISPOSING TO CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA 	1 Olivia Marini Verona	 IDENTIFICATION OF GRANULOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS (G-MDSCS) IN THE PERIPHERAL BLOOD OF HODGKIN AND NON-HODGKIN LYMPHOMA PATIENTS 	17 Laura Cicconi Roma	TREATED WITH LENALIDOMIDE AFTER FRONT-LINE THERAPY • PML-RARα KINETICS AND IMPACT OF FLT3-ITD MUTATIONS IN NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ATRA	13 Massimiliano Gambella Genova	CASES • NEGATIVE PRE TRANSPLANT MINIMAL RESIDUAL DISEASE, ASSESSED BY FLOW CYTOMETRY, IMPROVES OUTCOME IN ADULT ACUTE
8 Giada Biddeci Padova	 FEATURES OF AVASCULAR OSTEONECROSIS IN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKAEMIA: EXPERIENCE IN A SINGLE CENTER 	2 Marzia Cavalli <mark> Roma</mark>	 COMPARATIVE ANALYSIS BETWEEN RQ-PCR AND DIGITAL DROPLET PCR OF BCL2/IGH REARRANGEMENT IN THE PERIPHERAL BLOOD AND BONE MARROW OF STAGE I/II FOLLICULAR LYMPHOMA 	18 Maria Chiara Fontana Bologna	AND ATO OR ATRA AND CHEMOTHERAPY • CHROMOTHRIPSIS IN ACUTE MYELOID LEUKEMIA IS STRONGLY	14 Irene Dogliotti Torino	LYMPHOBLASTIC LEUKEMIA, ESPECIALLY IF CLEARENCE IS ACHIEVED EARLY DURING INDUCTION • MYD88L265P MUTATION DETECTION IN WALDENSTRÖM
9 Nice Turazzi Monza	BAFF RECEPTOR (BAFF-R) CAR-REDIRECTED T CELLS: A NOVEL TOOL TO ERADICATE HIGH RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) AAATOLIED AND MICHAEL LINES ATED DONOR COMPARED TO	3 Manuel Gotti Pavia	INTEGRATED MOLECULAR AND CLINICAL PROFILING TO OPTIMIZE OUTCOME PREDICTION IN SPLENIC MARGINAL ZONE LYMPHOMA	19 Michela Asperti Brescia	ASSOCIATED WITH POOR PROGNOSIS AND WITH TP53 ALTERATIONS • HEPARINS AS HEPCIDIN MODULATORS FOR ANEMIA OF INFLAMMATION	14 Treffe Dogitotti Tofffio	MACROGLOBULINEMIA BY DROPLET DIGITAL PCR: MINIMAL RESIDUAL DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING
10 Francesco Saraceni Ancona • MATCHED AND MISMATCHED UNRELATED DONOR COMPARED TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION: A RETROSPECTIVE, PROPENSITY SCORE-WEIGHTED ANALYSIS FROM THE ALWP OF THE EBMT		4 Elena Pomari Padova5 Giulia Corradi Bologna	 NPM-ALK EXPRESSION LEVELS IDENTIFY TWO DISTINCT SUBTYPES OF 		EMBRE ORE 16,45	FREE DNA 15 Fary Diop Novara • DIFFUSE LARGE B-CELL LYMPHOMA GENOTYPING ON THE LIQUID BIOPSY 16 Giovanni Roti Boston (Usa) • A LEUKEMIA-SELECTIVE DELIVERY STRATEGY FOR MUTANT NOTCH1	
	THOI ENGITY SCORE-WEIGHTED ANALTSIS THOW THE ALVIT OF THE EDIVIT	3 Giulia Gorradi Dologiia	LEUKEMIC MESENCHYMAL STROMAL CELLS (MSCS): A MECHANISM REGULATING MSC/ACUTE MYELOID LEUKEMIA CELL CROSS TALK	1 Chiara Cavallini Verona	INTEGRATION OF B-CELL RECEPTOR-INDUCED ERK SIGNALING AND MUTATIONS OF SF3B1 GENE REFINES PROGNOSIS IN TREATMENT	17 Francesco Maura Milano	TARGETED THERAPY • WHOLE GENOME SEQUENCING OF PAIRED ASYMPTOMATIC-
AULA ROMA VENERDÌ 18 NOVEMBRE ORE 8,30 11 Valentina Gianfelici Roma • RNA SEQUENCING UNRAVELS THE GENETICS OF REFRACTORY/RELAPSED		6 Roberta Zini Modena	 MIR-382-5P CONTROLS HEMATOPOIETIC STEM CELL DIFFERENTIATION THROUGH THE DOWNREGULATION OF MXD1 	NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA 2 Andrea Ghelli Luserna Di Rorà Bologna PREXASERTIB, A CHK1/CHK2 INHIBITOR, INCREASES THE EFFECTIVENESS OF CONVENTIONAL THERAPY IN B. (T. CELL. PROCEDUTER ACUTE			SYMPTOMATIC MM SAMPLES REVEALS A GENOMIC LANDSCAPE WITH DIVERSE EVOLUTIONARY PATTERNS AND MUTATIONAL
valentina diameter mona	T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. PROGNOSTIC AND THERAPEUTIC IMPLICATIONS	7 Grazia Fazio Monza	 A VERSATILE RNA NGS TARGETED CAPTURE STRATEGY TO DETECT FUSION GENES IN ACUTE LYMPHOBLASTIC LEUKEMIA 	3 Chiara Cerrato Torino	OF CONVENTIONAL THERAPY IN B-/T- CELL PROGENITOR ACUTE LYMPHOBLASTIC LEUKEMIA • UPFRONT OR RESCUE TRANSPLANT IN NEWLY DIAGNOSED YOUNG	18 Ramona Cassin Milano	PROCESSES • IDELALISIB RAPIDLY IMPROVES PLATELETS FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
12 Nellina Maria Ausilia Andriano Catania	DISSECTING THE DNA REPAIR MACHINERY IN BIOLOGICAL SUBGROUPS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA	8 Mattia D'Agostino Torino	 SOMATIC MUTATIONS' PROFILE BY NEXT GENERATION SEQUENCING CONFERS PROGNOSTIC VALUE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: AN ANALYSIS FROM THE MMRF COMMPASS STUDY 	4 Caterina Ilari Roma	MULTIPLE MYELOMA PATIENTS: POOLED ANALYSIS OF 529 PATIENTS • COPY NUMBER ANALYSIS OF THE BIRC3 GENE BY DROPLET DIGITAL PCR	19 Elena Vendramini Padova	DIFFERENTIALLY EXPRESSED NON-CODING RNA IMPROVES CLASSIFICATION OF ERG-RELATED PEDIATRIC B CELL PRECURSOR ACUTE
13 Francesca Schieppati Brescia	 INTRAVENOUS IMMUNOGLOBULIN (IVIG) IS AN EFFECTIVE TREATMENT FOR T-CELL-MEDIATED IMMUNE CYTOPENIAS IN MYELODYSPLASTIC SYNDROMES (MDS) AND OTHER BONE MARROW FAILURE (BMF) SYNDROMES 	9 Silvia Salmoiraghi Bergamo	TP53 GENE MUTATIONS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA DO NOT AFFECT THE HEMATOLOGIC RESPONSE ACHIEVEMENT BUT IS ASSOCIATED WITH EARLY RELAPSE AND VERY POOR PROGNOSIS	5 Giacomo Oliveira Milano	IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 110 DELETION • TRACKING GENETICALLY ENGINEERED LYMPHOCYTES LONG-TERM REVEALS THE DYNAMICS OF T-CELL IMMUNOLOGICAL MEMORY	20 Giuseppe Lia Torino	LYMPHOBLASTIC LEUKEMIA • EXTRACELLULAR VESICLES AS POTENTIAL BIOMARKER FOR ACUTE GRAFT-VERSUS-HOST-DISEASE
14 Rosario Di Maggio Palermo	• β-THALASSEMIA HETEROZYGOTE STATE DETRIMENTALLY AFFECTS HEALTH EXPECTATION AND MORTALITY - β-THALASSEMIA HETEROZYGOTE STATE DETRIMENTALLY AFFECTS HEALTH EXPECTATION AND MORTALITY			6 Francesco Mendicino Cosenza	 LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (RD) VERSUS BORTEZOMIB, MELPHALAN, PREDNISONE (VMP) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE STUDY 		